The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.
 
Natasha B. Leighl
Honoraria - Beigene; BMS; Janssen; MSD Oncology; Takeda
Research Funding - AstraZeneca Canada (Inst); Inivata/NeoGenomics (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Hiroaki Akamatsu
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Janssen; Sandoz
Research Funding - Amgen (Inst); Chugai Pharma (Inst)
 
Sun Min Lim
Honoraria - Boehringer Ingelheim; Takeda; Yuhan
Research Funding - Janssen Research & Development
 
Ying Cheng
No Relationships to Disclose
 
Anna Rachel Minchom
Honoraria - GlaxoSmithKline; Janssen; Merck; Seagen
Consulting or Advisory Role - Faron Pharmaceuticals; GlaxoSmithKline; Janssen Oncology; MSD
Research Funding - Astex Pharmaceuticals (Inst); Merck (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Melina Elpi Marmarelis
Stock and Other Ownership Interests - Johnson & Johnson; Merck
Honoraria - AstraZeneca; Blueprint Medicines; Janssen Oncology; Novocure; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bristol-Myers Squibb/Celgene; Ikena Oncology; Janssen Oncology; Regeneron
Research Funding - AstraZeneca (Inst); Genentech (Inst); Ikena Oncology (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Regeneron
 
Rachel E. Sanborn
Honoraria - Curio Science; Illumina; MJH Life Sciences; Targeted Oncology
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; EMD Serono; G1 Therapeutics; GE Healthcare; Gilead Sciences; GlaxoSmithKline; Illumina; Janssen Oncology; Lilly; Macrogenics; Regeneron; Sanofi/Aventis
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); Merck
 
James Chih-Hsin Yang
Honoraria - Amgen (Inst); AstraZeneca; AstraZeneca/MedImmune (Inst); BeiGene (Inst); Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca (Inst); Dizal Pharma (Inst); Gilead Sciences (Inst); Lilly; MSD; MSD Oncology (Inst); Novartis; Ono Pharmaceutical; Pfizer; Pfizer (Inst); Roche; Roche/Genentech (Inst); Sanofi/Regeneron (Inst); Taiho Pharmaceutical (Inst); Takeda; Takeda (Inst)
Consulting or Advisory Role - Abbvie; Amgen; Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Bayer; Bayer (Inst); Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Daiichi Sankyo/Astra Zeneca (Inst); G1 Therapeutics; Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hansoh; Incyte; Janssen Oncology (Inst); Lilly (Inst); Merck KGaA (Inst); MSD Oncology; MSD Oncology (Inst); Novartis; Novartis (Inst); Ono Pharmaceutical; Pfizer; Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda; Takeda (Inst); Yuhan
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Baogang Liu
No Relationships to Disclose
 
Tom John
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
Consulting or Advisory Role - Amgen (Inst); AstraZeneca; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; Ignyta; Merck KGaA; MSD Oncology; Novartis; Pfizer; PharmaMar (Inst); Roche/Genentech; Seagen (Inst); Specialised Therapeutics
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche; Roche
 
Bartomeu Massuti
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Janssen; Merck Serono; Roche
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Pfizer; Roche; Sanofi/Regeneron
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; MSD Oncology; Roche
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
John Xie
Employment - Janssen
Stock and Other Ownership Interests - JJ Innovative Medicine
 
Debropriya Ghosh
Employment - Janssen
Stock and Other Ownership Interests - JJ Innovative Medicine
 
Ali Alhadab
Employment - Janssen
Stock and Other Ownership Interests - JJ Innovative Medicine
 
Remy B Verheijen
Employment - Janssen
Stock and Other Ownership Interests - JJ Innovative Medicine
 
Mohamed Gamil
Employment - Janssen
Stock and Other Ownership Interests - JJ Innovative Medicine
 
Joshua Michael Bauml
Employment - Janssen
Stock and Other Ownership Interests - JJ Innovative Medicine
 
Mahadi Baig
Employment - Janssen
Stock and Other Ownership Interests - JJ Innovative Medicine
 
Antonio Passaro
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Johnson & Johnson/Janssen; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo Europe GmbH; Johnson & Johnson/Janssen; MSD Oncology